Stating that nothing untoward has been reported during Oxford vaccine candidate trials in India, Serum Institute CEO Adar Poonawalla has said that halting of the trial in the United Kingdom will have no impact on the production in India. The Serum Institute of India is conducting trials of the Oxford vaccine also known as COVISHIELD. Poonawalla told India Today that the reaction that has been reported is not directly linked to the vaccine and the person who has had the reaction had an existing neurological condition. He said during a vaccine trial such events are common. The CEO emphasised that his company’s production timelines are on schedule as planned.